Ranexa (previously Latixa) (ranolazine)
- Region
- 🇪🇺 EU
- Active substance
- ranolazine
- Company
- Menarini International Operations Luxembourg S.A. (MIOL)
- Status
- Authorised
- Therapeutic area
- Angina Pectoris
- EU approval
- Tue 08 Jul 2008
- Application
- EMEA/H/C/000805
- ATC
- C01EB18
- Official record
- www.ema.europa.eu
Indication
Ranexa is indicated as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti-anginal therapies (such as beta-blockers and / or calcium antagonists).
Regulatory milestones
No milestones recorded in the last year.
Follow Ranexa (previously Latixa)
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.